Article Text
Statistics from Altmetric.com
- anticoagulants
- aspirin
- atrial fibrillation
- cerebrovascular accident
- platelet aggregation inhibitors
- biphenyl compounds
- tetrazoles
- ticlopidine
Q In patients with atrial fibrillation (AF), is clopidogrel plus aspirin non-inferior to oral anticoagulation for preventing vascular events?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Haematology ★★★★★★★
METHODS
Design:
randomised controlled trial (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events [ACTIVE W]).
Allocation:
concealed.*
Blinding:
blinded (outcome assessors and monitoring committee).*
Follow up period:
median 1.28 years.
Setting:
30 clinical centres worldwide.
Patients:
6706 patients (mean age 70 y, 66% men) with AF and ⩾1 of the following criteria: age ⩾75 years; receiving treatment for systemic hypertension; previous stroke, transient ischaemic attack, or non-central nervous system (non-CNS) systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; peripheral arterial disease; or age 55–74 years with diabetes mellitus requiring drug therapy …
Linked Articles
- Glossary